Gene Engineering in Stem Cells for Drug Discovery and Therapeutic
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 3371
Special Issue Editor
Interests: stem cell CRISPR editing; stem cell therapeutics; allogeneic manufacturing; CAR-T/NK cells; stem cell proteomics/genomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gene engineering technologies from viral vector-mediated to protein-based editing such as ZFN, TALENs, and CRISPR/Cas systems have been improved significantly. These technologies with stem cells have facilitated drug discovery and have resulted in the development of promising curative therapies for many intractable diseases. They can efficiently correct genetic errors; however, these technologies have limitations, such as off-target effects and possible safety issues, which need to be considered when employing these techniques in humans and animals. Significant efforts have been made to overcome these limitations and to accelerate the clinical implementation of these technologies.
In this way, the recent technological advancements in gene engineering and their applications in stem cells are developing to enable the efficient discovery of drugs and treatment of intractable diseases.
The main relevant topics for this Special Issue are:
- Precise gene editing techniques
- Safe and efficient therapeutics development
- Application of gene engineering platform in drug discovery
- Novel techniques in gene engineering
- Preclinical and clinical studies, etc.
Prof. Dr. Bonghee Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- stem cells
- gene editing
- CRISPR-Cas
- TALEN
- drug discovery
- therapeutics development
